**CASE REPORT**

**High-grade myofibroblastic sarcoma of the pleura: A case report and literature review**

Ruizhi Zhao1, Jianyang Wang1, Hongtu Zhang2, Yihebali Chi3 & Nan Bi1

1 Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

2 Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

3 Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

**Keywords**
Chemoradiotherapy; high-grade myofibroblastic sarcoma; pleura.

**Abstract**
High-grade myofibroblastic sarcoma (HGMS) is a rare cancer that has high recurrence and metastatic rates. Here, we report the first case of HGMS originating from the pleura. Based on the findings of pleural biopsy, pathological examination and immunohistochemical staining, grade III myofibroblastic sarcoma (MS) was diagnosed. The patient underwent eight cycles of chemotherapy (epirubicin and ifosfamide), followed by radiotherapy. As of May 2020, the patient had been followed for six months and no tumor progression had occurred.

**Key points:** This is the first report of high-grade myofibroblastic sarcoma originating from the pleura. The patient was treated via nonsurgical strategies, including chemotherapy and radiotherapy.

**Introduction**
Malignant sarcoma consisting of myofibroblasts or exhibiting myofibroblastic differentiation is diagnosed as myofibroblastic sarcoma (MS). MS is a rare disease that typically originates in the head and neck, extremities, and the trunk.1 MS can be divided into low-, intermediate- and high-grade types according to the morphologic features.2,3 The former two types together are classified as low-grade myofibroblastic sarcoma by the WHO, but high-grade MS (HGMS), which is also called pleomorphic myofibrosarcoma,2 has not as yet been included in the WHO classification. HGMS is diagnosed by cytomorphological analysis and immunophenotyping, and has higher recurrence and metastatic rates than low-grade MS.2 Previous studies on HGMS are rare, and to the best of our knowledge, no case of HGMS in the pleura has been reported in the English-language literature. Therefore, here we report the first case of HGMS originating from the pleura.
Case report

In November 2018, a 57-year-old female patient presented to our hospital with a two-month history of cough and shortness of breath. Her medical records revealed that she did not have a history of tuberculosis, malignancy, or chemoradiotherapy. Whole-body positron emission tomography/computed tomography (PET/CT) scan revealed thickened right pleura (standard uptake value [SUV] = 23) and a hypermetabolic mass (10.9 × 9.5 cm) with a clear boundary in the right lung (max SUV = 29) (Fig 1a & b).

The level of the serum tumor markers progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) was 71.66 pg/mL (upper normal limit, 69.2) and 68.99 ng/mL (upper normal limit, 16.3). The other markers were within the normal range. Pleural biopsy was performed, and pathological examination of the biopsy sample showed spindle cell sarcoma in the right pleura. Immunohistochemical staining revealed that the sample was positive for smooth muscle actin (SMA) (2+, Fig 2c), CD99 (2+), and Bcl-2 (2+), and negative for desmin (Fig 2d), ALK, CD31, CD34, CR, MyoDI, S-100, and WT1. Additionally, the Ki67 value was 70% (Fig 2a & b). Based on these findings, the patient was diagnosed with grade III MS.

After consultation with a multidisciplinary team, the patient was administered eight cycles of chemotherapy with epirubicin (100 mg day 1) and ifosfamide (2 g day 1) every 21 days. CT evaluation after chemotherapy showed a partial response: the lesion had shrunk to 5.2 × 2.0 cm (Fig 1c). The patient was then administered radiotherapy. The planning gross target volume (PGTV) was determined by delineating the internal gross tumor volume (IGTV) on four-dimensional CT simulation images and expanding it by 3 mm. The clinical tumor volume (CTV) was determined by delineating the pleural region involving the tumor before chemotherapy. The planning target volume (PTV) was created by 4-mm isotropic expansion of the IGTV and CTV. TOMO therapy was used to deliver a total dose of 50.4 Gy to the PGTV in 28 fractions, and a dose of 60.2 Gy to the PTV in 28 fractions.

One month after radiotherapy, an enhanced CT scan showed that the tumor had not progressed (Fig 1d). However, the ProGRP and NSE levels had normalized. After six-month follow-up, of May 2020, no tumor progression was noted.

Discussion

This is the first report of HGMS in the pleura. HGMS is usually immunopositive for SMA, muscle-specific actin, vimentin, and fibronectin, and it is occasionally positive for desmin. Further, it is immunonegative for h-caldesmon, CK, laminin, S100, and CD34. In our case, the tumor was positive for SMA and negative for desmin, S100, CR, and CD34. Thus, the immunohistochemical findings are similar to those reported in the literature.

Surgical excision with wide margins is the most effective definitive treatment for MS, but adjuvant therapies, including chemotherapy and radiotherapy, are also considered. In a report by Cai and colleagues on 46 cases of MS in the head and neck region, four patients with HGMS, who had undergone partial excision, experienced relapse and died. Wen et al. and Anastasiou et al. reported two cases of HGMS in two uncommon sites—the
liver and the paratesticular soft tissues. Both patients underwent surgical resection and did not require any postoperative treatment. No recurrence was recorded at the six-month follow-up. In 2008, Seiji et al.\textsuperscript{16} reported a case of primary HGMS in the pericardium that was treated with thoracotomy, followed by postoperative chemotherapy (one cycle of doxorubicin and ifosfamide) and radiotherapy (50 Gy) (which were necessitated by incomplete resection). The residual tumor gradually regressed, and compression of the left atrium was relieved. No progression or adverse effects were noted till six months after the surgery. The present case is the first case of HGMS arising from the pleura in which only chemotherapy and RT were administered, and surgical treatment was not performed. The tumor responded well to treatment, and no relapse occurred for up to four months after RT.

There are no standard guidelines for the treatment of HGMS, as it a rare malignant tumor. Further, there is limited clinical information on the outcomes of nonsurgical treatment, such as chemotherapy and RT. Therefore, this case provides new information that could potentially be useful for similar rare cases.

**Acknowledgments**

This work was supported by CAMS Key Laboratory of Translational Research on Lung Cancer (grant no. 2018PT31035).

**Disclosure**

None of the authors have any conflicts of interest to report.

**References**

1. Coffin CM, Alaggio R. Fibroblastic and myofibroblastic tumors in children and adolescents. *Pediatr Dev Pathol* 2012; 15 (Suppl 1): 127–80.
2. Fisher C. Myofibroblastic malignancies. *Adv Anat Pathol* 2004; 11 (4): 190–201.
3. Fisher C. Myofibrosarcoma. *Virchows Arch* 2004; 445 (3): 215–23.
4. Eyden B, Banerjee SS, Shenjere P, Fisher C. The myofibroblast and its tumours. *J Clin Pathol* 2009; 62 (3): 236–49.
5. Meng GZ, Zhang HY, Bu H, Yang GH, Zhang XL, Yang G. Myofibroblastic sarcoma of the nasal cavity and paranasal sinus: A clinicopathologic study of 6 cases and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2007; 104 (4): 530–9.
6. Fisher C, Montgomery E, Healy V. Calponin and h-caldesmon expression in synovial sarcoma; the use of calponin in diagnosis. *Histopathology* 2003; 42 (6): 588–93.
7. Montgomery E, Goldblum JR, Fisher C. Myofibrosarcoma: A clinicopathologic study. *Am J Surg Pathol* 2001; 25 (2): 219–28.
8. Montgomery E, Fisher C. Myofibroblastic differentiation in malignant fibrous histiocytoma (pleomorphic myofibrosarcoma): A clinicopathological study. *Histopathology* 2001; 38 (6): 499–509.
Myofibroblastic sarcoma of the pleura

9 Ceballos KM, Nielsen GP, Selig MK, O’Connell JX. Is anti-h-caldesmon useful for distinguishing smooth muscle and myofibroblastic tumors? An immunohistochemical study. *Am J Clin Pathol* 2000; 114 (5): 746–53.

10 Pereira DOD, Da SE, de Souza LB et al. Myofibroblastic lesions in the oral cavity: Immunohistochemical and ultrastructural analysis. *Oral Dis* 2019; 25 (1): 174–81.

11 Watanabe K, Ogura G, Tajino T, Hoshi N, Suzuki T. Myofibrosarcoma of the bone: A clinicopathologic study. *Am J Surg Pathol* 2001; 25 (12): 1501–7.

12 Takacsi-Nagy Z, Murakozy G, Pogany P, Fodor J, Orosz Z. Myofibroblastic sarcoma of the base of tongue. Case report and review of the literature. *Strahlenther Onkol* 2009; 185 (3): 198–201.

13 Cai C, Dehner LP, El-Mofty SK. In myofibroblastic sarcomas of the head and neck, mitotic activity and necrosis define grade: A case study and literature review. *Virchows Arch* 2013; 463 (6): 827–36.

14 Wen J, Zhao W, Li C, Shen JY, Wen TF. High-grade myofibroblastic sarcoma in the liver: A case report. *World J Gastroenterol* 2017; 23 (38): 7054–8.

15 Anastasiou I, Levis PK, Katafigiotis I et al. High grade myofibroblastic sarcoma of paratesticular soft tissues. *Case Rep Oncol Med* 2014; 2014: 768379.

16 Koga S, Ikeda S, Urate J et al. Primary high-grade myofibroblastic sarcoma arising from the pericardium. *Circ J* 2008; 72 (2): 337–9.